Nature Subjournal Forecasts Top 10 Best-Selling Drugs Globally for 2026

12Month10Day,Nature Reviews Drug DiscoveryPublished an article predicting that2026The Top Ten Best-Selling Drugs Worldwide in [Year].

2026Annual Best-Selling Drug ForecastTOP10

Note: The forecast data only covers sales booked by designated global marketing partners, such as dupilumab handled by Sanofi.Dupixent) andBMSResponsible for apixaban (Eliquis). Related estimates are based on the seller's stock analyst model and byEvaluate PharmaSummarize to form consensus views.

a. QlexPembrolizumab (pembrolizumab) Subcutaneous injection formulation, its approved indications are the same as the original intravenous injection formulation.KeytrudaSame;

b. MounjaroAndZepboundAll with tirzepatide (tirezpatide) as the active ingredient, respectively approved for the treatment of2Type 2 Diabetes and Obesity;

c. OzempicAndWegovyAll with semaglutide (semaglutide) as the active ingredient, respectively approved for the treatment of2Type 2 Diabetes and Obesity.

Compared to last year2025Compared with the forecast for the year,2026YearTOP10The list of products has not changed, showing the stability of the leading group. However, the internal ranking of the products will see significant adjustments. It is worth noting that these ten drugs are expected to...2026Annual Total Creation1980Billion dollars in sales, compared to2025Annual Forecast1680billion USD, with an increase of up to18%, with a strong growth momentum.

Oncology Field, MSD'sPD-1Monoclonal AntibodyKeytruda/Qlex(Pembrolizumab)It is expected that338Hundreds of millions of dollars in sales continue to top the list, including the newly launched subcutaneous injectable formulation.QlexWill Contribute25hundred million dollars. As a new dosage form drug,QlexRegarded by Merck as a response to its intravenous formulationKeytrudaIn2028Key strategies for market competition after the patent expiration this year, and has been approved withKeytrudaExactly the same indications. Despite its solid position, it is predicted that,KeytrudaMonotherapy(ExcludingQlex）Sales in2026The year may see the first year-on-year decline.

ExceptKeytrudaBesides, another product that has made its way intoTOP10The tumor drug is from Johnson & Johnson.CD38Monoclonal AntibodyDarzalex(Daratumumab). Its sales are expected to exceed160billion dollars, and continues to maintain its growth momentum, consolidating its leading position in the multiple myeloma market.

Metabolic Diseases FieldThe drug in2025The year saw continued rapid growth, and it is expected that2026This trend will continue in the coming years.

Eli Lilly's Tirzepatide（tirzepatide）"The 'Double Star' performed the most brilliantly. Used for2Type diabetesMounjaroExpected sales will reach258billion dollars, jumping to the second place on the list; and for obesityZepboundIt is expected to become the fifth best-selling drug and becomeTOP10With the highest absolute sales and year-on-year growth rate in China“King of Growth”If the sales of these two drugs with the same active ingredients are combined, the total amount will exceed450billion dollars, surpassing the top of the listKeytruda。

In contrast, Novo Nordisk's semaglutide（semaglutide）ProductOzempic(For diabetes) Due to market competition, the forecast has been revised downward. Its2026Projected annual sales are197Billion USD, ranking dropped to sixth place.

Field of Immunological Diseases, AbbVie'sSkyriziand SanofiDupixentIt is expected to further enhance their respective rankings in the list through significant sales growth.

The bottom of the list also reflects the dynamic changes in the market.Gilead'sHIVCompound TherapyBiktarvyDespite continuous sales growth, its ranking is expected to decline due to faster growth of other drugs.BMSAnticoagulantEliquisAfter losing the market exclusivity period, the ranking continued to decline.

References:

https://www.nature.com/articles/d41573-025-00203-x

Copyright © 2025 PHARMCUBE. All Rights Reserved.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.